American Regent’s HEART-FID trial for INJECTAFER fails to meet primary endpoint

American Regent, Inc., a subsidiary of Daiichi Sankyo Group, has announced disappointing results from its phase 3 HEART-FID trial of INJECTAFER (ferric carboxymaltose injection) for ... Read More